主要终点-话题@MedSci

#主要终点#

97篇内容 | 2149人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1996984, encodeId=aac119969847c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, objectType=article, longId=205711, objectId=ced5205e1160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced5205e1160, replyNumber=0, likeNumber=67, createdTime=2021-02-13, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced5205e1160, moduleTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced5205e1160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996991, encodeId=e5551996991b5, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Mirikizumab达到溃疡性结肠炎研究的主要终点, objectType=article, longId=208641, objectId=2249208641f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2249208641f7, replyNumber=0, likeNumber=62, createdTime=2021-07-15, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2249208641f7, moduleTitle=Mirikizumab达到溃疡性结肠炎研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2249208641f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996978, encodeId=2d3b19969e840, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, objectType=article, longId=198983, objectId=4d33198983b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d33198983b2, replyNumber=0, likeNumber=58, createdTime=2021-01-08, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d33198983b2, moduleTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d33198983b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Faricimab治疗AMD，III期研究达到主要终点, objectType=article, longId=206377, objectId=aef72063e733, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aef72063e733, replyNumber=0, likeNumber=63, createdTime=2021-12-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aef72063e733, moduleTitle=Faricimab治疗AMD，III期研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aef72063e733)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996983, encodeId=1e1c1996983cb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, objectType=article, longId=205617, objectId=b61a20561e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61a20561e2a, replyNumber=0, likeNumber=90, createdTime=2021-02-06, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61a20561e2a, moduleTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61a20561e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996977, encodeId=1da119969e713, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=达格列净III期DAPA-CKD试验达到所有主要终点和次要终点, objectType=article, longId=198399, objectId=7f8819839938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8819839938, replyNumber=0, likeNumber=59, createdTime=2021-04-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8819839938, moduleTitle=达格列净III期DAPA-CKD试验达到所有主要终点和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8819839938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996967, encodeId=e83b199696ef1, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=62, createdTime=2020-02-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996969, encodeId=3b7d19969691c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, objectType=article, longId=187657, objectId=c23618e6572f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23618e6572f, replyNumber=0, likeNumber=58, createdTime=2020-03-05, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23618e6572f, moduleTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c23618e6572f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996973, encodeId=e12119969e3d3, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, objectType=article, longId=192692, objectId=46461926922a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46461926922a, replyNumber=0, likeNumber=121, createdTime=2021-01-21, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46461926922a, moduleTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46461926922a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996960, encodeId=035319969605e, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点, objectType=article, longId=183345, objectId=0b1c18334534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b1c18334534, replyNumber=0, likeNumber=54, createdTime=2020-05-15, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b1c18334534, moduleTitle=Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b1c18334534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996965, encodeId=3d1d19969658b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, objectType=article, longId=185517, objectId=d8b718551ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b718551ed7, replyNumber=0, likeNumber=67, createdTime=2020-09-08, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b718551ed7, moduleTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b718551ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996976, encodeId=9dcf19969e687, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点, objectType=article, longId=196006, objectId=cc5f1960069e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc5f1960069e, replyNumber=0, likeNumber=57, createdTime=2020-06-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc5f1960069e, moduleTitle=非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc5f1960069e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996979, encodeId=3b6b19969e905, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=46, createdTime=2021-05-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996971, encodeId=d7d319969e179, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Radiother Oncol：中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析 , objectType=article, longId=192082, objectId=2ce019208213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ce019208213, replyNumber=0, likeNumber=79, createdTime=2021-02-05, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ce019208213, moduleTitle=Radiother Oncol：中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ce019208213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996970, encodeId=964e19969e0f6, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点, objectType=article, longId=189427, objectId=cb2d18942e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d18942e7b, replyNumber=0, likeNumber=56, createdTime=2020-03-15, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d18942e7b, moduleTitle=Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d18942e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996974, encodeId=62ce19969e479, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点, objectType=article, longId=194505, objectId=e08f19450510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08f19450510, replyNumber=0, likeNumber=62, createdTime=2020-12-21, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08f19450510, moduleTitle=JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08f19450510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996963, encodeId=be731996963bc, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=PET成像剂PyL在前列腺癌的III期CONDOR试验中达到主要终点, objectType=article, longId=185152, objectId=4ea418515287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea418515287, replyNumber=0, likeNumber=92, createdTime=2020-03-13, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea418515287, moduleTitle=PET成像剂PyL在前列腺癌的III期CONDOR试验中达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea418515287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996958, encodeId=a6d91996958c7, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, objectType=article, longId=179450, objectId=b45b1e9450d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45b1e9450d9, replyNumber=0, likeNumber=59, createdTime=2020-01-25, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45b1e9450d9, moduleTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45b1e9450d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996957, encodeId=bd2d199695ed2, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, objectType=article, longId=178809, objectId=55521e880970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55521e880970, replyNumber=0, likeNumber=80, createdTime=2020-06-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55521e880970, moduleTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55521e880970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996955, encodeId=151c199695553, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=阿斯利康的三联疗法Breztri Aerosphere治疗晚期COPD达到了主要终点, objectType=article, longId=178351, objectId=9a9a1e83512e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9a1e83512e, replyNumber=0, likeNumber=63, createdTime=2019-11-22, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9a1e83512e, moduleTitle=阿斯利康的三联疗法Breztri Aerosphere治疗晚期COPD达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9a1e83512e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

主要终点

2020-05-29

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点

2021-02-13

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Mirikizumab达到溃疡性结肠炎研究的主要终点

2021-07-15

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到

2021-01-08

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Faricimab治疗AMD，III期研究达到主要终点

2021-12-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳

2021-02-06

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

达格列净III期DAPA-CKD试验达到所有主要终点和次要终点

2021-04-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2020-02-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点

2020-03-05

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点

2021-01-21

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点

2020-05-15

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点

2020-09-08

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点

2020-06-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2021-05-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Radiother Oncol：中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析

2021-02-05

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点

2020-03-15

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点

2020-12-21

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

PET成像剂PyL在前列腺癌的III期CONDOR试验中达到主要终点

2020-03-13

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点

2020-01-25

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点

2020-06-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

阿斯利康的三联疗法Breztri Aerosphere治疗晚期COPD达到了主要终点

2019-11-22

科室
- - 订阅+
  - 更多科室
工具
服务